The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Forecasted Market Value Of The Deoxycholic Acid Obesity Drugs Market Across 2026–2030?
The deoxycholic acid obesity drugs market has witnessed significant growth in recent years. Its value is anticipated to increase from $0.5 billion in 2025 to $0.57 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.4%. Historically, this expansion has been propelled by factors such as enhanced consumer understanding of aesthetic treatments, the proliferation of medical aesthetics clinics, an increasing inclination towards minimally invasive procedures, the availability of approved deoxycholic acid formulations, and a rise in disposable income.
The deoxycholic acid obesity drugs market is projected to experience substantial expansion in the coming years, forecast to reach $0.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.1%. Factors driving this growth include a heightened demand for customized aesthetic solutions, the broader application of combined aesthetic protocols, a greater emphasis on body sculpting techniques, increased funding for innovative aesthetic drugs, and deeper market penetration in developing regions. Key trends anticipated during this period involve the wider acceptance of non-invasive fat reduction methods, an escalating need for injectable aesthetic therapies, the progression of combined lipolytic treatments, the proliferation of body contouring services offered by clinics, and a stronger emphasis on aesthetic results tailored to individual patients.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28192&type=smp
What Drivers Are Shaping The Future Growth Of The Deoxycholic Acid Obesity Drugs Market?
The increasing prevalence of obesity is projected to boost the expansion of the deoxycholic acid obesity drug market. Obesity rates define the proportion of individuals within a population categorized as overweight or obese, determined by their body mass index (BMI). The escalation in obesity rates stems from unhealthy eating patterns, including the frequent consumption of processed foods and sweetened beverages, which leads to the accumulation of surplus calories as body fat. Deoxycholic acid obesity drugs contribute to lowering these rates by dissolving and eliminating superfluous fat cells, leading to specific fat reduction and enhanced body shape. For example, in May 2025, data from the Office for Health Improvement and Disparities, a UK-based government body, indicated that between 2023 and 2024, approximately 64.5% of adults aged 18 and above in England were either overweight or obese, marking an increase from 64.0% recorded between 2022 and 2023. Consequently, the escalating obesity rates are fueling the growth of the deoxycholic acid obesity drug market.
What Segmentation Levels Are Considered In The Deoxycholic Acid Obesity Drugs Market?
The deoxycholic acid obesity drugs market covered in this report is segmented –
1) By Drug Type: ATX-101 (Deoxycholic Acid Injection Or Kybella Or Belkyra), Experimental Or Compounded Deoxycholic Acid Formulations, Combination Therapies, Oral Deoxycholic Acid Products
2) By Formulation: Injectable, Topical
3) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Pharmacies
4) By Application: Submental Fat Reduction, Abdominal Fat Reduction, Thighs Arms And Flanks, Lipomas And Localized Fat, Cellulite Management
5) By End-User: Aesthetic Clinics, Dermatology Clinics, Plastic Surgery Centers, Hospitals, Home Administration
Subsegments:
1) By ATX-101 (Deoxycholic Acid Injection or Kybella or Belkyra): Standard Injectable, High-Purity Formulations, Combination Injection Therapies
2) By Experimental Or Compounded Deoxycholic Acid Formulation: Clinical Trial Formulations, Compounded Customized Formulations
3) By Combination Therapies: Deoxycholic Acid + Lipolytic Agents, Deoxycholic Acid + Enzyme Therapy
4) By Oral Deoxycholic Acid Products: Capsules, Tablets, Liquid Formulations
What Trends Are Projected To Affect The Deoxycholic Acid Obesity Drugs Market?
Leading companies operating in the deoxycholic acid obesity drug market are focusing on developing advanced products, such as injectable deoxycholic acid obesity drugs, to enhance treatment efficacy and improve patient outcomes. These injectable drugs leverage deoxycholic acid, a substance that breaks down fat cells, and are administered via injection to specifically target and reduce fat in particular areas. For instance, in March 2024, LG Chem Ltd., a South Korea-based chemicals company, launched Bellacholine for the reduction of submental fat. This non-surgical injection is specifically formulated to diminish moderate to severe submental fat (double chin) by safely destroying fat cells with deoxycholic acid. It provides benefits like a body-compatible pH, minimal sedimentation, and stimulates skin elasticity through collagen synthesis.
Which Leading Firms Are Contributing To The Growth Of The Deoxycholic Acid Obesity Drugs Market?
Major companies operating in the deoxycholic acid obesity drugs market are AbbVie Inc., Cipla Ltd., Glenmark Life Sciences Limited, Curia Global Inc., Daewoong Pharmaceutical Co. Ltd., Actylis, ICE Pharma, Cayman Chemical Company, Nacalai Tesque Inc., Sichuan Huiyu Pharmaceutical, Conscientia Industrial, Manus Aktteva Biopharma LLP, Jeevan Chemicals & Pharmaceuticals, Anhui Chem-Bright Bioengineering Co. Ltd., GlpBio Technology LLC, Legere Pharmaceuticals, Otto Chemie Pvt. Ltd., BOC Sciences, Guangzhou Green Cross Pharmaceutical, Prodotti Chimici e Alimentari S.P.A
Read the full deoxycholic acid obesity drugs market report here:
Which Geographic Regions Are Influencing Demand In The Deoxycholic Acid Obesity Drugs Market?
North America was the largest region in the deoxycholic acid obesity drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the deoxycholic acid obesity drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Deoxycholic Acid Obesity Drugs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28192&type=smp
Browse Through More Reports Similar to the Global Deoxycholic Acid Obesity Drugs Market 2026, By The Business Research Company
Metabolic Disorders Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report
Weight Loss Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/weight-loss-drugs-global-market-report
Weight Loss Supplements Market Report 2026
https://www.thebusinessresearchcompany.com/report/weight-loss-supplements-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model